Drug Discovery

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

IBM, KPMG, Merck and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the US Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the US.

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

Ligand Pharmaceuticals and PhoreMost have announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Dassault Systèmes to buy Medidata Solutions for £4.5bn

Dassault Systèmes has signed an agreement to acquire US-based Medidata Solutions for an enterprise value of $5.8bn (£4.5bn).

Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins.

Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

AptarGroup has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical, for a combined enterprise value of approximately $50m (£39.3m).

Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

Merck has signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m).

nference enters into R&D data science partnership with Janssen

nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.

Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m).

Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies

Lantheus Holdings has collaborated with NanoMab Technology to provide a novel biomarker for clinical development and management of immuno-oncology therapies.